167 related articles for article (PubMed ID: 31639426)
1. Small molecule inhibition of Ewing sarcoma cell growth via targeting the long non coding RNA HULC.
Mercatelli N; Fortini D; Palombo R; Paronetto MP
Cancer Lett; 2020 Jan; 469():111-123. PubMed ID: 31639426
[TBL] [Abstract][Full Text] [Related]
2. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
3. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B
Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472
[TBL] [Abstract][Full Text] [Related]
4. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
5. MiR-708-5p is inversely associated with EWS/FLI1 Ewing sarcoma but does not represent a prognostic predictor.
Roberto GM; Vieira GM; Delsin LEA; Silva MO; Hakime RG; Engel EE; Scrideli CA; Tone LG; Brassesco MS
Cancer Genet; 2019 Jan; 230():21-27. PubMed ID: 30470587
[TBL] [Abstract][Full Text] [Related]
6. MiR-193b, downregulated in Ewing Sarcoma, targets the ErbB4 oncogene to inhibit anchorage-independent growth.
Moore C; Parrish JK; Jedlicka P
PLoS One; 2017; 12(5):e0178028. PubMed ID: 28542597
[TBL] [Abstract][Full Text] [Related]
7. Genotoxic stress inhibits Ewing sarcoma cell growth by modulating alternative pre-mRNA processing of the RNA helicase DHX9.
Fidaleo M; Svetoni F; Volpe E; Miñana B; Caporossi D; Paronetto MP
Oncotarget; 2015 Oct; 6(31):31740-57. PubMed ID: 26450900
[TBL] [Abstract][Full Text] [Related]
8. Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.
Kovar H
Expert Opin Ther Targets; 2014 Nov; 18(11):1315-28. PubMed ID: 25162919
[TBL] [Abstract][Full Text] [Related]
9. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
[TBL] [Abstract][Full Text] [Related]
10. Long noncoding RNA EWSAT1-mediated gene repression facilitates Ewing sarcoma oncogenesis.
Marques Howarth M; Simpson D; Ngok SP; Nieves B; Chen R; Siprashvili Z; Vaka D; Breese MR; Crompton BD; Alexe G; Hawkins DS; Jacobson D; Brunner AL; West R; Mora J; Stegmaier K; Khavari P; Sweet-Cordero EA
J Clin Invest; 2014 Dec; 124(12):5275-90. PubMed ID: 25401475
[TBL] [Abstract][Full Text] [Related]
11. PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.
Giorgi C; Boro A; Rechfeld F; Lopez-Garcia LA; Gierisch ME; Schäfer BW; Niggli FK
Oncotarget; 2015 Oct; 6(30):28895-910. PubMed ID: 26336820
[TBL] [Abstract][Full Text] [Related]
12. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma.
Stegmaier K; Wong JS; Ross KN; Chow KT; Peck D; Wright RD; Lessnick SL; Kung AL; Golub TR
PLoS Med; 2007 Apr; 4(4):e122. PubMed ID: 17425403
[TBL] [Abstract][Full Text] [Related]
13. Development of an Ewing sarcoma cell line with resistance to EWS‑FLI1 inhibitor YK‑4‑279.
Conn E; Hour S; Allegakoen D; Graham G; Petro J; Kouassi-Brou M; Hong SH; Selvanathan S; Çelik H; Toretsky J; Üren A
Mol Med Rep; 2020 Mar; 21(3):1667-1675. PubMed ID: 32016454
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and structure-activity relationship studies of small molecule disruptors of EWS-FLI1 interactions in Ewing's sarcoma.
Tosso PN; Kong Y; Scher L; Cummins R; Schneider J; Rahim S; Holman KT; Toretsky J; Wang K; Üren A; Brown ML
J Med Chem; 2014 Dec; 57(24):10290-303. PubMed ID: 25432018
[TBL] [Abstract][Full Text] [Related]
15. Long Non-Coding RNA HULC Promotes Progression of Bone Neoplasms.
Zhang T; Wan CY; Mei XL; Jia P; Wang MJ
Med Sci Monit; 2018 Aug; 24():5754-5760. PubMed ID: 30120220
[TBL] [Abstract][Full Text] [Related]
16. An Oral Formulation of YK-4-279: Preclinical Efficacy and Acquired Resistance Patterns in Ewing Sarcoma.
Lamhamedi-Cherradi SE; Menegaz BA; Ramamoorthy V; Aiyer RA; Maywald RL; Buford AS; Doolittle DK; Culotta KS; O'Dorisio JE; Ludwig JA
Mol Cancer Ther; 2015 Jul; 14(7):1591-604. PubMed ID: 25964201
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Ewing's sarcoma using an antisense oligodeoxynucleotide to regulate the cell cycle.
Asami S; Chin M; Shichino H; Yoshida Y; Nemoto N; Mugishima H; Suzuki T
Biol Pharm Bull; 2008 Mar; 31(3):391-4. PubMed ID: 18310898
[TBL] [Abstract][Full Text] [Related]
18. miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy.
Nakatani F; Ferracin M; Manara MC; Ventura S; Del Monaco V; Ferrari S; Alberghini M; Grilli A; Knuutila S; Schaefer KL; Mattia G; Negrini M; Picci P; Serra M; Scotlandi K
J Pathol; 2012 Apr; 226(5):796-805. PubMed ID: 21960059
[TBL] [Abstract][Full Text] [Related]
19. Transcriptome profiling of Ewing sarcomas - treatment resistance pathways and IGF-dependency.
Chen Y; Hesla AC; Lin Y; Ghaderi M; Liu M; Yang C; Zhang Y; Tsagkozis P; Larsson O; Haglund F
Mol Oncol; 2020 May; 14(5):1101-1117. PubMed ID: 32115849
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiling of peripheral blood cells: new insights into Ewing sarcoma biology and clinical applications.
Przybyl J; Kozak K; Kosela H; Falkowski S; Switaj T; Lugowska I; Szumera-Cieckiewicz A; Ptaszynski K; Grygalewicz B; Chechlinska M; Pienkowska-Grela B; Debiec-Rychter M; Siedlecki JA; Rutkowski P
Med Oncol; 2014 Aug; 31(8):109. PubMed ID: 25008066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]